Coming up with candidate drugs is the easiest part of the process. It’s possible that that could be improved a little (not sped up, but suggesting compounds in silico less likely to fail) and possibly have suggestions for scale up, but those are all hard, and the latter is less amenable to being “read” during trains phase.

This has been one of the target AI applications since the 1960s.

(Former drug developer who will never touch the life sciences again)